Zai Lab Limited (ZLAB)Healthcare | Biotechnology | Pudong, China | NasdaqGM
26.82 USD
+0.79
(3.035%)
⇧
(Aug. 27, 2026, 4 p.m.
EDT)
After hours: 27.10 +0.28 (1.044%) ⇧ (Aug. 27, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:50 a.m. EDT
The investment case for Zai Lab is currently paralyzed by a severe fundamental disconnect. Despite a 'strong buy' analyst consensus and a recent surge in stock price (+99% YoY), the company is bleeding cash with negative free cash flow, shrinking revenues (-3%), and negative operating margins. The balance sheet is fragile, with debt-to-equity nearing 42% and no dividend support. This creates a dangerous dichotomy: the market is pricing in a turnaround based on the oncology pipeline, but the quarterly financials tell a story of deterioration. The short-term outlook remains neutral-to-cautious because the recent price rally has stalled, and the statistical forecasting models show no directional edge. More importantly, the options market is screaming caution; traders are buying deep out-of-the-money puts as insurance, indicating they expect volatility to turn negative soon. There is no momentum here to fuel a high-conviction entry yet. Long-term, the business quality is unproven. The multi-year trajectory shows a volatile rollercoaster rather than a sustained compounder, and the lack of profitability makes it impossible to rate as a core holding. Until the company demonstrates consistent revenue growth and a path to profitability, it remains a speculative bet on a future cure rather than a current investment in a profitable business. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.096439 |
| AutoETS | 0.096439 |
| MSTL | 0.097174 |
| AutoTheta | 0.105380 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 9.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.360 |
| Excess Kurtosis | 0.55 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 41.937 |
| Revenue per Share | 4.057 |
| Market Cap | 3,010,980,096 |
| Forward P/E | -12.71 |
| Beta | 0.78 |
| Profit Margins | -41.86% |
| Website | https://www.zailaboratory.com |
As of Aug. 22, 2026, 5:50 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (over 2,000 contracts at strikes below $20) compared to negligible call volume. While there is some new call flow at lower strikes ($15-$22.50), the overwhelming capital allocation is defensive, suggesting a fear of further decline rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.19211668 |
| Address1 | Building B |
| Address2 | 899 Halei Road |
| All Time High | 193.54 |
| All Time Low | 13.48 |
| Ask | 23.88 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,238,110 |
| Average Daily Volume3 Month | 1,026,196 |
| Average Volume | 1,026,196 |
| Average Volume10Days | 1,238,110 |
| Beta | 0.781 |
| Bid | 13.12 |
| Bid Size | 2 |
| Book Value | 5.963 |
| City | Pudong |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | China |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.82 |
| Current Ratio | 2.133 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 27.2 |
| Day Low | 26.575 |
| Debt To Equity | 41.937 |
| Display Name | Zai Lab |
| Earnings Call Timestamp End | 1,786,017,600 |
| Earnings Call Timestamp Start | 1,786,017,600 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -248,168,000 |
| Ebitda Margins | -0.55196 |
| Enterprise To Ebitda | -10.67 |
| Enterprise To Revenue | 5.89 |
| Enterprise Value | 2,648,034,304 |
| Eps Current Year | -2.19529 |
| Eps Forward | -2.11033 |
| Eps Trailing Twelve Months | -1.7 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 20.9354 |
| Fifty Day Average Change | 5.8845997 |
| Fifty Day Average Change Percent | 0.2810837 |
| Fifty Two Week Change Percent | -19.211668 |
| Fifty Two Week High | 34.72 |
| Fifty Two Week High Change | -7.9000015 |
| Fifty Two Week High Change Percent | -0.22753459 |
| Fifty Two Week Low | 15.96 |
| Fifty Two Week Low Change | 10.86 |
| Fifty Two Week Low Change Percent | 0.6804511 |
| Fifty Two Week Range | 15.96 - 34.72 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,505,914,200,000 |
| Float Shares | 96,831,867 |
| Forward Eps | -2.11033 |
| Forward P E | -12.708912 |
| Free Cashflow | -83,963,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 1,784 |
| Fullday Change | 0.789999 |
| Fullday Change Percent | 3.03496 |
| Fullday Price | 27.1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.03778 |
| Gross Profits | 16,985,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.021540001 |
| Held Percent Institutions | 0.38386002 |
| Implied Shares Outstanding | 112,266,228 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China. |
| Long Name | Zai Lab Limited |
| Market | us_market |
| Market Cap | 3,010,980,096 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_271123063 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -188,212,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,878,790,160 |
| Number Of Analyst Opinions | 12 |
| Open | 27.11 |
| Operating Cashflow | -133,384,000 |
| Operating Margins | -0.71948 |
| Payout Ratio | 0.0 |
| Phone | 86 21 6163 2588 |
| Post Market Change | 0.2800007 |
| Post Market Change Percent | 1.0439996 |
| Post Market Price | 27.1 |
| Post Market Time | 1,787,873,402 |
| Previous Close | 26.03 |
| Price Eps Current Year | -12.217064 |
| Price Hint | 2 |
| Price To Book | 4.497736 |
| Price To Sales Trailing12 Months | 6.696811 |
| Profit Margins | -0.41861 |
| Quick Ratio | 1.611 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.789999 |
| Regular Market Change Percent | 3.03496 |
| Regular Market Day High | 27.2 |
| Regular Market Day Low | 26.575 |
| Regular Market Day Range | 26.575 - 27.2 |
| Regular Market Open | 27.11 |
| Regular Market Previous Close | 26.03 |
| Regular Market Price | 26.82 |
| Regular Market Time | 1,787,860,801 |
| Regular Market Volume | 597,324 |
| Return On Assets | -0.14745 |
| Return On Equity | -0.26911 |
| Revenue Growth | -0.033 |
| Revenue Per Share | 4.057 |
| Sand P52 Week Change | 0.18053913 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 112,266,228 |
| Shares Percent Shares Out | 0.0665 |
| Shares Short | 7,465,887 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 6,351,893 |
| Short Name | Zai Lab Limited |
| Short Percent Of Float | 0.0679 |
| Short Ratio | 7.8 |
| Source Interval | 15 |
| Symbol | ZLAB |
| Target High Price | 50.0 |
| Target Low Price | 24.25 |
| Target Mean Price | 33.14 |
| Target Median Price | 31.84 |
| Total Cash | 617,521,984 |
| Total Cash Per Share | 5.501 |
| Total Debt | 254,576,000 |
| Total Revenue | 449,614,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.674074 |
| Two Hundred Day Average Change | 7.1459255 |
| Two Hundred Day Average Change Percent | 0.36321533 |
| Type Disp | Equity |
| Volume | 597,324 |
| Website | https://www.zailaboratory.com |
| Zip | 201,203 |